Eli Lilly and Company· @EliLillyandCo · X·· 24 天前AI 评分42
AI 导读
近70%的晚期卵巢癌女性患者会出现复发。在#ESMO26上,我们分享了在铂敏感卵巢癌女性患者中开展的在研抗体偶联药物(ADC)的新数据。 了解更多:https://go.lilly.com/nghre6
正文
Nearly 70% of women with advanced ovarian cancer see it return. At #ESMO26, we shared new data from our investigational antibody-drug conjugate in women with platinum-sensitive ovarian cancer.
Learn more: https://go.lilly.com/nghre6
来源:Eli Lilly and Company · x.com